Quantitative Analysis Of Lactobacillus SPP. And Bifidobacterium SPP. Among Type 2 Diabetes Individuals Receiving A Microbial Cell Preparation Supplement, A Randomized Controlled Trial
Aim: Thegut microbiota composition of Type 2 Diabetes individuals is linked with insulin resistance. In animal
studies and human clinical trials, different strains of Lactobacillus and Bifidobacteriumcould exert beneficial effects on
glycemic control. However, the quantities of Bifidobacterium and Lactobacillusin the fecal sample of individuals with Type
2 Diabetes have not yet been determined. Therefore, this randomized, double-blind, controlled clinical trial aimed to
determine the quantities of Bifidobacterium and Lactobacillus in fecal samples of individuals with Type 2 Diabetes receiving
a multistrain microbial cell preparation.
Method: A total of 40individuals with Type 2 Diabetes, aged 30-70 years old, were randomly assigned to receive either
multistrain (3 strains of Lactobacillus and 3 strains of Bifidobacterium) microbial cell preparation (probiotic)(n=20) or
placebo (n=20) for 12 weeks. Plate count method was used to quantify the Lactobacillus and BifidobacteriumColony
Forming Units (CFUs) in fecal sample before and after intervention. Phenotype and genotype methods were utilized to
confirm the accuracy of the counted colonies. General linear model analysis of variance was conducted on data considering
grouping as between factor effect.
Results: Subjects were comparable at baseline characteristics. Mean fasting blood glucose andglycated hemoglobin were
higher than the target goal. The quantities of Lactobacilluswere1.8×107 ±0.7×107CFU/gr and6.4×106 ± 1.1×106CFU/grin the
Placebo Group and Probiotic Group, respectively. The quantities of Bifidobacteriumwere2.7×106 ± 5.2×106and3.4×106 ±
0.2×106inthe Placebo Group and Probiotic Group, respectively. The increase in CFUs of Lactobacillus was not significant in
Placebo Group, but it increased significantly in Probiotic Group. While the CFUs of Bifidobacterium increased marginally
(almost 2-fold) in the Placebo Group, they increased significantly (4.5-fold) in the Probiotic Group
Conclusion - The multistrain probiotic supplement had successfully passed through the gastrointestinal tract.
Keywords - Lactobacillus spp., Lactobacillus spp., gut microbiota, Type 2 Diabetes Mellitus.